Aurobindo Pharma to divest its US entity Natrol to New Mountain Capital
The all-cash transaction which is valued at $550 million (4,048 crore) is expected to close by January 2021
Hyderabad: Hyderabad-based Aurobindo Pharma has reached a definitive agreement to sell Natrol LLC., a wholly-owned subsidiary of Aurobindo Pharma USA, Inc., to an affiliate of New Mountain Capital to combine with Jarrow Formulas.
The all-cash transaction is valued at $550 million (or Rs 4,048 crore at the current exchange rate). Subject to customary closing conditions and regulatory approvals, the transaction is expected to close by January 2021.
Natrol’s annual sales for the 12 months ended March 31, 2020 was about $157 million. Following the acquisition of the assets of Natrol by Aurobindo Pharma in December 2014, Natrol has been a consistently profitable business, growing on all fronts under Aurobindo’s ownership.
“Aurobindo is committed to evaluating and concluding strategic options towards focused portfolio enhancement with the ultimate objective of enhancing stakeholder values. We are pleased to sell the Natrol business to an outstanding private equity player, who could focus additional resources to grow Natrol, its products and brands further,” the company said in a statement.
“On behalf of Aurobindo Group, my heartful thanks to all stakeholders including employees, who have supported in acquiring and bringing Natrol to a growth path in the past six years,” said N Govindarajan, MD, Aurobindo Pharma.
He also said “Proceeds from Natrol’s divestiture will be used to reduce debt and other new strategic initiatives.”
Jefferies served as the sole financial advisor to Aurobindo, and Sullivan & Cromwell acted as legal counsel to Aurobindo.
Now you can get handpicked stories from Telangana Today on Telegram everyday. Click the link to subscribe.
Click to follow Telangana Today Facebook page and Twitter .
